Patients will need to be monitored during the treatment course with documentation of acute toxicity. No treatment related toxicities are usually seen other than mild fatigue. Brisk skin reaction can be anticipated with extremity superficial sarcomas. Fibrosis and lymphedema are long term concerns. Nausea has been reported in abdominal sarcomas and is managed conservatively with prophylactic or therapeutic antiemetics.

Periodic clinical and radiological follow up is warranted based on institutional protocol. A 1 month baseline toxicity and response assessment clinical follow up and MRI, followed by 3–6 month assessment in the first couple of years and less often thereafter is advised. Adverse events and radiological assessments need to be carefully monitored and recorded.

The role of SBRT for sarcomas is evolving. Systematic study on prospective studies are warranted to assess comparative effectiveness, toxicity, cost benefit and quality of life benefits, Better understanding of dose fractionation and radiobiology will help define definitive role for SBRT for sarcomas.